New
and Emerging Technologies: Improved Laboratory and On-Site
Detection of OIE List A Viruses in Animals and Animal Products
Detection of OIE List A Viruses in Animals and Animal Products
Produced by Macom
Sweden 2005-2008
Last updated: June 9 2008
Sweden 2005-2008
Last updated: June 9 2008
Plan for Exploitation and Dissemination Activities
The
involvement of nine partner laboratories, one third party and two subcontractors,
representing diagnostic institutes, universities, one SME and an international
organisation of the United Nations (IAEA, FAO) provides guarantee that
the gained knowledge will be directly applied in routine diagnostic laboratories,
in undergraduate and postgraduate teaching, in industries, as well as in
national and in international networks of biotechnology and health sciences.
Dissemination and exploitation of the results is considered by this new consortium to be a vital component of the proposed work programme. This is reflected in a work package dedicated to “Transfer of knowledge to EU member and candidate countries, as well as to third countries”. Information dissemination will be carried out on a number of levels.
Internal dissemination. Similarly to our FP5 project QLK2CT-2000-00486, an internal education system will be established in the project, in order to provide possibilities to members to visit other partner laboratories. The purpose is to learn and practice the new methods and adapt them in their home institutes. Partners 3 and 4 will be in charge to continue this well-functioning practice, as dedicated in a separate subworkpackage in WP9.
External dissemination. Results generated will be specifically targeted at veterinary institutions, both central laboratories and simply equipped units. Practitioners will be informed on the new methods by publications in the veterinary and farming press and meetings with consortia of veterinarians working in the “front line” in the field or at abattoirs. Good lines of communication between consortium members and veterinary institutes, universities, veterinary health authorities and industrial companies inside and outside the EU in relation to improved diagnosis of viral diseases have already been established by members of this consortium.
Dissemination and exploitation of the results is considered by this new consortium to be a vital component of the proposed work programme. This is reflected in a work package dedicated to “Transfer of knowledge to EU member and candidate countries, as well as to third countries”. Information dissemination will be carried out on a number of levels.
Internal dissemination. Similarly to our FP5 project QLK2CT-2000-00486, an internal education system will be established in the project, in order to provide possibilities to members to visit other partner laboratories. The purpose is to learn and practice the new methods and adapt them in their home institutes. Partners 3 and 4 will be in charge to continue this well-functioning practice, as dedicated in a separate subworkpackage in WP9.
External dissemination. Results generated will be specifically targeted at veterinary institutions, both central laboratories and simply equipped units. Practitioners will be informed on the new methods by publications in the veterinary and farming press and meetings with consortia of veterinarians working in the “front line” in the field or at abattoirs. Good lines of communication between consortium members and veterinary institutes, universities, veterinary health authorities and industrial companies inside and outside the EU in relation to improved diagnosis of viral diseases have already been established by members of this consortium.
The
participation of a multinational organisation as third party in the
consortium (FAO/IAEA Joint Division) will enhance these communications and experts
with established global network of information will participate in the
worldwide dissemination of information. The consortium has formally agreed
with the FAO/IAEA Joint Division that information will be disseminated
to third country veterinary institutions through their global information
dissemination network.
Where applicable, scientific information will be disseminated in peer-reviewed international journals and international scientific meetings. The scientific committee will unanimously approve all submissions for publications in journals and meetings.
Dissemination of results at a policy level will also be relevant to this project and will occur through progress reports to the EU and, where necessary meetings between the co-ordinator and other members of the consortium with EU and national policy groups. Commercial exploitation of the results generated will be within the consortium and led by our commercial partner. Terms and agreements relating to foreground and background information in the project and exploitation of results will be detailed in a consortium agreement.
Any and all IPR opportunities arising within the project will be identified by the group and filed by our commercial partner who will have first refusal on exploitation of eventual commercial products. Our commercial partner will carry all costs of patent applications and/or defence, which are relevant to their commercial interests. This arrangement will reflect EU policy and guidelines related to IPR and exploitation of results within a EU-funded project. It is anticipated that production and marketing of commercial products derived from this project will be beyond the time scale of the project, but will be substantially accelerated by results generated within the project. All members of the consortium will have royalty free access to reagents and kits generated from the present research.
Where applicable, scientific information will be disseminated in peer-reviewed international journals and international scientific meetings. The scientific committee will unanimously approve all submissions for publications in journals and meetings.
Dissemination of results at a policy level will also be relevant to this project and will occur through progress reports to the EU and, where necessary meetings between the co-ordinator and other members of the consortium with EU and national policy groups. Commercial exploitation of the results generated will be within the consortium and led by our commercial partner. Terms and agreements relating to foreground and background information in the project and exploitation of results will be detailed in a consortium agreement.
Any and all IPR opportunities arising within the project will be identified by the group and filed by our commercial partner who will have first refusal on exploitation of eventual commercial products. Our commercial partner will carry all costs of patent applications and/or defence, which are relevant to their commercial interests. This arrangement will reflect EU policy and guidelines related to IPR and exploitation of results within a EU-funded project. It is anticipated that production and marketing of commercial products derived from this project will be beyond the time scale of the project, but will be substantially accelerated by results generated within the project. All members of the consortium will have royalty free access to reagents and kits generated from the present research.